TScan Therapeutics, Inc.

TCRX · Healthcare

$0.67

Capitalización: 45.16M USDRendimiento por dividendo: —
Advance¿Es buen momento para comprar TScan Therapeutics, Inc.? Pregunta a Copenvest AIObtén una lectura Advance con IA sobre timing, riesgo y qué hacen los inversores rastreados.Preguntar a Copenvest AI

Cargando gráfico…

Noticias

Últimos titulares de esta acción

BioPharma Dive4 sept 2026, 9:00

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

InvestorsHub2 sept 2026, 12:30

TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

GlobeNewswire2 sept 2026, 11:00

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

Simply Wall St.26 ago 2026, 19:08

Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?

Zacks12 ago 2026, 12:10

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates